Invion Ltd (IVX) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.163x

Based on the latest financial reports, Invion Ltd (IVX) has a cash flow conversion efficiency ratio of -0.163x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.34 Million ≈ $-951.19K USD) by net assets (AU$8.25 Million ≈ $5.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IVX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Invion Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Invion Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Invion Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Invion Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Antelope Enterprise Holdings Ltd
NASDAQ:AEHL
0.191x
Australia United Mining Ltd
AU:AYM
-0.054x
Aminex PLC
STU:DOP
-0.014x
Zynex Inc
NASDAQ:ZYXI
0.152x
ZW Data Action Technologies Inc
NASDAQ:CNET
-0.067x
Awilco Drilling PLC
OL:AWDR
0.616x
Marna Beteiligungen AG
F:M5S
N/A
Zoomcar Holdings Inc.
NASDAQ:ZCAR
0.131x

Annual Cash Flow Conversion Efficiency for Invion Ltd (2006–2025)

The table below shows the annual cash flow conversion efficiency of Invion Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Invion Ltd worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$8.25 Million
≈ $5.84 Million
AU$-2.97 Million
≈ $-2.10 Million
-0.360x -116.34%
2024-06-30 AU$14.44 Million
≈ $10.22 Million
AU$-2.40 Million
≈ $-1.70 Million
-0.166x -68.80%
2023-06-30 AU$18.40 Million
≈ $13.02 Million
AU$-1.81 Million
≈ $-1.28 Million
-0.099x -73.98%
2022-06-30 AU$19.58 Million
≈ $13.85 Million
AU$-1.11 Million
≈ $-784.62K
-0.057x -164.92%
2021-06-30 AU$4.79 Million
≈ $3.39 Million
AU$417.98K
≈ $295.74K
0.087x +410.95%
2020-06-30 AU$5.43 Million
≈ $3.84 Million
AU$-152.47K
≈ $-107.88K
-0.028x +92.73%
2019-06-30 AU$5.46 Million
≈ $3.86 Million
AU$-2.11 Million
≈ $-1.49 Million
-0.386x -531.44%
2018-06-30 AU$7.91 Million
≈ $5.59 Million
AU$707.09K
≈ $500.31K
0.089x +245.01%
2017-06-30 AU$4.01 Million
≈ $2.84 Million
AU$-247.14K
≈ $-174.87K
-0.062x +90.36%
2016-06-30 AU$5.99 Million
≈ $4.24 Million
AU$-3.83 Million
≈ $-2.71 Million
-0.640x +56.67%
2015-06-30 AU$6.86 Million
≈ $4.85 Million
AU$-10.13 Million
≈ $-7.17 Million
-1.477x -244.59%
2014-06-30 AU$10.16 Million
≈ $7.19 Million
AU$-4.35 Million
≈ $-3.08 Million
-0.429x -36.75%
2013-06-30 AU$11.04 Million
≈ $7.81 Million
AU$-3.46 Million
≈ $-2.45 Million
-0.313x +82.26%
2012-06-30 AU$6.01 Million
≈ $4.25 Million
AU$-10.62 Million
≈ $-7.51 Million
-1.766x -128.12%
2011-06-30 AU$-2.14 Million
≈ $-1.52 Million
AU$-13.46 Million
≈ $-9.52 Million
6.281x +97.36%
2010-06-30 AU$-4.78 Million
≈ $-3.38 Million
AU$-15.20 Million
≈ $-10.76 Million
3.182x +4.10%
2008-06-30 AU$-3.23 Million
≈ $-2.28 Million
AU$-9.86 Million
≈ $-6.98 Million
3.057x +117.84%
2007-06-30 AU$715.28K
≈ $506.11K
AU$-12.26 Million
≈ $-8.67 Million
-17.134x -597.95%
2006-06-30 AU$4.83 Million
≈ $3.42 Million
AU$-11.87 Million
≈ $-8.40 Million
-2.455x --

About Invion Ltd

AU:IVX Australia Drug Manufacturers - Specialty & Generic
Market Cap
$2.61 Million
AU$3.68 Million AUD
Market Cap Rank
#29650 Global
#1726 in Australia
Share Price
AU$0.04
Change (1 day)
+4.88%
52-Week Range
AU$0.04 - AU$0.15
All Time High
AU$4.80
About

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more